THE ROLE OF PCSK9 INHIBITORS IN HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES
Keywords:
PCSK9 inhibitors; hyperlipidemia; LDL cholesterol; atherosclerosis; evolocumab; alirocumab; cardiovascular outcomes.Abstract
Background: Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Objective: To summarize the mechanisms, efficacy, cardiovascular outcomes, safety, and clinical positioning of monoclonal antibody PCSK9 inhibitors, with attention to hepatic impairment. Methods: A narrative review of the clinical trials FOURIER and ODYSSEY OUTCOMES, the 2019 ESC/EAS dyslipidaemia guideline and its 2025 focused update, and product labeling. Results: In FOURIER, evolocumab reduced LDL-C by 59% relative to placebo at 48 weeks and reduced the primary composite cardiovascular endpoint (9.8% vs 11.3%; hazard ratio 0.85). In ODYSSEY OUTCOMES, alirocumab reduced the primary endpoint after acute coronary syndrome (9.5% vs 11.1%; hazard ratio 0.85). Conclusions: PCSK9 monoclonal antibodies provide substantial additional LDL-C lowering and reduce cardiovascular events in selected high-risk populations. Evidence does not establish a special clinical advantage in advanced liver disease; treatment must follow individual assessment and product labeling [1–4, 6].
References
1.Sabatine M. S., Giugliano R. P., Keech A. C. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease // The New England Journal of Medicine. — 2017. — Vol. 376, no. 18. — P. 1713–1722. — DOI: 10.1056/NEJMoa1615664.
2.Schwartz G. G., Steg P. G., Szarek M. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome // The New England Journal of Medicine. — 2018. — Vol. 379, no. 22. — P. 2097–2107. — DOI: 10.1056/NEJMoa1801174.
3.Mach F., Baigent C., Catapano A. L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk // European Heart Journal. — 2020. — Vol. 41, no. 1. — P. 111–188. — DOI: 10.1093/eurheartj/ehz455.
4.Mach F., Koskinas K. C., Roeters van Lennep J. E. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias // European Heart Journal. — 2025. — Vol. 46, no. 42. — P. 4359–4378. — DOI: 10.1093/eurheartj/ehaf190.
5.Ference B. A., Ginsberg H. N., Graham I. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies // European Heart Journal. — 2017. — Vol. 38, no. 32. — P. 2459–2472. — DOI: 10.1093/eurheartj/ehx144.
6.REPATHA (evolocumab): prescribing information [Electronic resource] / U.S. Food and Drug Administration. — 2026. — URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125522s049lbl.pdf (accessed: 12.09.2026).
